1. Home
  2. GGR vs ADAG Comparison

GGR vs ADAG Comparison

Compare GGR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

N/A

Current Price

$3.95

Market Cap

47.7M

ML Signal

N/A

Logo Adagene Inc.

ADAG

Adagene Inc.

N/A

Current Price

$3.42

Market Cap

146.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGR
ADAG
Founded
2011
2011
Country
Taiwan
China
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.7M
146.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GGR
ADAG
Price
$3.95
$3.42
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$8.00
AVG Volume (30 Days)
17.6K
63.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.07
$3,688.61
Revenue Next Year
N/A
$17.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.33
52 Week High
$6.21
$3.53

Technical Indicators

Market Signals
Indicator
GGR
ADAG
Relative Strength Index (RSI) 60.41 67.06
Support Level $3.63 $1.64
Resistance Level $4.23 N/A
Average True Range (ATR) 0.38 0.34
MACD 0.12 -0.02
Stochastic Oscillator 43.54 40.02

Price Performance

Historical Comparison
GGR
ADAG

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.

Share on Social Networks: